OSE Immunotherapeutics Unveils Strategic Plan for 2026 - 2028
OSE Immunotherapeutics has revealed its strategic plan for the period 2026 - 2028, focusing on four value creation levers, with an emphasis on the development of its immunology programs.
Advancements in Key Clinical Trials
According to the press release, OSE Immunotherapeutics has announced the progression of the pivotal phase 3 study of Tedopi® in non-small cell lung cancer, with results expected in the first quarter of 2028. This study will require limited financial resources. The company also plans to develop Lusvertikimab in new rare indications using an intravenous formulation, while adopting a precision medicine approach. These projects aim to limit costs while maximizing the potential of the treatment.
Strategic Shifts in Drug Formulation
OSE Immunotherapeutics plans to transition to a subcutaneous formulation of Lusvertikimab for the treatment of ulcerative colitis, due to market preference for oral and subcutaneous formulations. The company intends to license this asset after obtaining bioequivalence data. Additionally, the company continues to capitalize on its differentiated research platform to drive innovation in rare indications and explore combination strategies for Lusvertikimab.
Financial Projections and Partnerships
The company anticipates securing sufficient cash reserves to cover its operations until the start of the fourth quarter of 2026. OSE Immunotherapeutics may receive a milestone payment of 17.5 million euros from Boehringer Ingelheim, related to the acquisition of an anti-PD-1/cytokine cis-targeting asset. The company will also continue to explore new partnerships for its assets to maximize financing opportunities.
